GlassScriptPhysician profile
Maxim A Polansky
NPI 1275913006
$3,677.85
in general payments reported to CMS, 2019-2025
26 companies · $1,550 in 2025
The $1,550 reported for 2025 was more than what 84% of Mohs-Micrographic Surgery providers received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $123 · 2023: $837 · 2024: $1,168 · 2025: $1,550.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,455 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,454.78 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $578.81 | 2023-2025 | |
| Janssen Biotech, INC. | $329.47 | 2023-2025 | Tremfya, Stelara, Simponi Aria |
| Regeneron Healthcare Solutions, INC. | $317.77 | 2023-2025 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $317.34 | 2023-2025 | |
| Arcutis Biotherapeutics, INC. | $254.07 | 2024-2025 | Zoryve |
| Genzyme Corporation | $248.10 | 2023-2025 | |
| Mayne Pharma Commercial LLC | $233.28 | 2025 | |
| Incyte Corporation | $213.40 | 2023-2024 | Opzelura |
| Dermavant Sciences, INC. | $191.38 | 2024 | Vtama |
| Pfizer INC. | $182.96 | 2023-2025 | |
| Sun Pharmaceutical Industries INC. | $125.67 | 2024-2025 | |
| Allergan, INC. | $123.08 | 2020 | |
| Lilly USA, LLC | $97.33 | 2023 | Olumiant |
| Amgen INC. | $64.81 | 2024-2025 | Otezla, Otezla |
| Kerecis Limited | $63.89 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $51.86 | 2025 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $43.77 | 2024-2025 | Cabtreo, Jublia, Siliq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.82 | 2024 | Spevigo |
| Galderma Laboratories, L.P. | $33.18 | 2024-2025 | Nemluvio |
| Ucb, INC. | $32.98 | 2024 | Bimzelx |
| Mimedx Group, INC. | $31.15 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $24.91 | 2024 | Sotyktu |
| Biofrontera INC. | $23.41 | 2023 | Ameluz, Xepi, Bf-Rhodoled |
| Leo Pharma INC. | $21.34 | 2025 | Adbry |
| Lnhc, INC | $18.29 | 2025 | Zelsuvmi |
| Journey Medical Corporation | $13.78 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maxim Polansky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.